ES-002 is under clinical development by Elpiscience Biopharma and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ES-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ES-002 overview
ES-002 is under development for the treatment of advanced or metastatic solid tumors including pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal adenocarcinoma, gastric cancer. It acts by targeting CD39. The drug candidate is developed based on human-driven immune profiling technology that enables to measure the function and expression of target. It is administered through intravenous route.
Elpiscience Biopharma overview
Elpiscience Biopharma is a clinical-stage biotech company that develops immunotherapies to treat cancer patients. The company’s pipeline products include ES101, ES102, ES104, ES002, ES004, ES005, ES009, ES014, and ES028 antibody. It carries out immune-oncology therapies and approaches, and translational medicine. Elpiscience Biopharma’s products are used for the treatment of solid tumors, including colorectal, pancreatic, gastric cancer, cholangiocarcinoma, and non-small cell lung cancer, among others. The company carries out research and development activities through Immunoshine, AbLego, and Bispecific Macrophage Engager Antibody BiME platforms. It partners with biopharmaceutical companies and academic institutions to accelerate the development of potentially transformative cancer immunotherapies. Elpiscience Biopharma is headquartered in Shanghai, China.
For a complete picture of ES-002’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - ES-002 in Non-Small Cell Lung Cancer
Premium Insights
The gold standard of business intelligence.
